BioStem Technologies (BSEM)
Manufacturer of placental-tissue allografts for wound care and surgical applications.
BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal
BioStem Technologies OTCMKTS: BSEM outlined its strategy to expand in surgical applications, shift its revenue mix away from physician-office wound care and bring manufacturing of acquired products into its Florida facility.
BioStem Technologies to Present at the Sidoti MicroCap Conference
POMPANO BEACH, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the Sidoti MicroCap Virtual Conference.
BioStem Technologies Q2 Earnings Call Highlights
BioStem Technologies OTCMKTS: BSEM reported second-quarter revenue of $7.9 million as the company continued its transition to a predominantly hospital-focused commercial model. Revenue increased from $6.1 million in the first quarter, supported by higher hospital sales, expanded commercial coverage and a full quarter of contribution from its acquired business.
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates
BioStem Technologies, Inc. (BSEM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to earnings of $0.11 per share a year ago.
BioStem Technologies Reports Second Quarter 2026 Financial Results
Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the second quarter ended June 30, 2026.
BioStem Technologies Announces Nasdaq Uplisting
POMPANO BEACH, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has completed its review of the Company's listing application and approved the Company's common stock for listing on The Nasdaq Capital Market.
BioStem Technologies to Host Second Quarter 2026 Financial Results Conference Call on August 12, 2026
POMPANO BEACH, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its second quarter 2026 financial results on Wednesday, August 12, 2026, and will host a conference call and webcast at 4:30 PM ET.
BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission
POMPANO BEACH, Fla., July 10, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the filing of a Form 10 registration statement (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) to register its shares of common stock pursuant to the Securities Exchange Act of 1934, as amended, and reaffirmed its strategic decision to pursue a listing on the Nasdaq Stock Market (“Nasdaq”).
BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies
Company Continues to Expand Intellectual Property Portfolio Supporting Advanced Placental Allograft Innovation POMPANO BEACH, FL / ACCESS Newswire / July 8, 2026 / BioStem Technologies, Inc. (OTCID:BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the United States Patent and Trademark Office (USPTO) has issued four U.S. design patents covering the Company's proprietary fenestrated human placental allograft technologies. The newly issued patents strengthen BioStem's intellectual property portfolio and provide additional protection for innovative allograft designs in surgical and wound care applications.
BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
POMPANO BEACH, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the Planet MicroCap Las Vegas 2026 Conference.
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
POMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the appointment of Mark Glickman, Steven D.
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor
POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million.
BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue Estimates
BioStem Technologies, Inc. (BSEM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.17 per share a year ago.
BioStem Technologies Reports First Quarter 2026 Financial Results
POMPANO BEACH, Fla., May 14, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the first quarter ended March 31, 2026.
BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026
POMPANO BEACH, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its first quarter 2026 financial results on Thursday, May 14, 2026, and will host a conference call and webcast at 4:30 PM ET.
BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026
POMPANO BEACH, Fla., April 08, 2026 (GLOBE NEWSWIRE) — BioStem Technologies® (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing and commercialization of perinatal tissue allograft products, today announced its participation in the Symposium on Advanced Wound Care (SAWC) Spring meeting in Charlotte, NC, from April 8-12.
BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026
POMPANO BEACH, Fla., April 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies® (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing and commercialization of perinatal tissue allograft products, today announced its participation in the Symposium on Advanced Wound Care (SAWC) Spring meeting in Charlotte, NC, from April 8-12.
BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference
POMPANO BEACH, Fla., March 31, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference.